Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

Clinical trial NCT04629703 · COMPLETED

Trial details

NCT number: NCT04629703
Sponsor: Rigel Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Covid19 SARS (Severe Acute Respiratory Syndrome)SARS Pneumonia SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere Pneumonia Pneumonia, Viral

Start date: 2021-03-25
Primary completion: 2022-09-05
Enrollment: 280

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.